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Department of Intensive Care, Erasme University hospital, Université Libre de Bruxelles, Brussels, BelgiumSepsis – deﬁned as a dysregulated immunological response to infec-
tion associated with some degree of associated organ dysfunction
(Vincent et al., 2013) – is a common problem and still complicated by
unacceptably high mortality rates. Infection is treated with antibiotics,
and source control when needed, but there is no effective, speciﬁc treat-
ment for sepsis. The only drug that has ever beenmarketed for this pur-
pose, drotrecogin alfa (activated), was probably efﬁcacious (Vincent,
2012), but was withdrawn, essentially because we could not identify
which patients would actually beneﬁt from it. This has been a key prob-
lem inmany sepsis trials. Indeed, over the years, sepsis has been consid-
ered primarily as a pro-inﬂammatory response, so we have focused on
controlling pro-inﬂammatory mediators, including cytokines, such as
tumour necrosis factor (TNF) and interleukin-1 (IL-1). However, there
is also an anti-inﬂammatory response, which occurs simultaneously
(Hotchkiss et al., 2013), and the initial greater pro-inﬂammatory effect
is rapidly followed by a state of immunosuppression (sometimes called
“immunoparalysis”). Giving an anti-TNF antibody to patientswho are al-
ready predominantly immunosuppressed is clearly not desirable and
may even be harmful. Similarly, giving the pro-inﬂammatory growth fac-
tor, granulocyte colony-stimulating factor (G-CSF), to all septic patients
was not associated with improved outcomes (Stephens et al., 2008).
It is clear that sepsis therapies need to be adapted to the individual
patient rather than directed at a general diagnosis of ‘sepsis’. The
study by Pena et al. (in press) in this issue of EBioMedicine represents
an important step in this direction. These investigators studied cellular
gene expression in peripheral blood mononuclear cells (PBMCs) from
septic patients. Using well established gene test approaches, they docu-
mented a clear and consistent endotoxin tolerance (also called cellular
reprogramming) signature in a series of almost 600 septic patients
from different cohorts. The group of investigators is reputed in this
ﬁeld and the results are convincing.
Importantly, cellular reprogramming is not limited to Gram-
negative infections and blood endotoxin levels are not increased only
in the presence of Gram-negative organisms (Marshall et al., 2004;
Buckley et al., 2006). The authors, therefore, proposed that cellular
reprogramming could be used as a diagnostic test for sepsis. This is
not straightforward conceptually though, because diagnosing sepsis☆ I declare that I have no conﬂicts of interest.
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sequences, and such a test is perhaps applied too late to be of use in fa-
cilitating early patient management. Cellular reprogramming may be
more helpful to estimate the risk of nosocomial infection than for sepsis
diagnosis (Conway Morris et al., 2013), and future studies should eval-
uate these changes prospectively in patients who are not infected at
the time of hospital admission.
The study (Pena et al., in press) has several limitations. Firstly, the
authors struggle somewhat with terms and concepts and oscillate be-
tween “infection” (a microbiological process typically recognised by
the presence of some host response including fever and altered white
blood count) and “sepsis” (a more severe form, typically characterised
by some degree of organ dysfunction). This is not surprising, because
they used the old 1991 criteria for sepsis, in which an infection with
fever and increasedWBCwas indeed called sepsis. Nevertheless, the ob-
servation that the sicker the patient, themore likely he/she was to have
endotoxin tolerance, suggests that this test may indeed represent a
marker of sepsis rather than simply infection. Secondly, few clinical
data are provided for the patients studied. Clearly, the investigators
started from the blood samples they had, rather than from the clinical
scenarios. Moreover, I am always puzzled when I see patients classiﬁed
in a dichotomised fashion into septic and non-septic, when in clinical
practice there are some patients in a “grey zone”, for whom we never
know, even at the end of the hospital stay, whether or not there was
truly an infection. A typical scenario is the critically ill patient receiving
mechanical ventilation who develops a febrile episode associated with a
vague chest inﬁltrate on X-ray, which could correspond to pneumonia
but could equally represent some pulmonary oedema or even atelectasis.
Nevertheless, despite these limitations, these data are novel and im-
portant, as they conﬁrm the common and early occurrence of immuno-
suppression following the onset of infection and cellular reprogramming
represents a ﬁrst step in the characterisation of cellular responses in
sepsis. Importantly, the deﬁnition of “early” sepsis remains difﬁcult.
Although more than 80% of the patients in this study were enrolled in
the emergency room (ER), suggesting that they were in the early
phase of disease, some patients may have been infected some time be-
fore reaching the ER; in most patients it is difﬁcult to know when the
pathologic process actually began, i.e., when the ‘sepsis clock’ started.
Better characterisation of these responses in individual patientswith
sepsis will help open the door to immunomodulating strategies, both
for clinical trial purposes in allowing better identiﬁcation of appropriate
patient cohorts, but also at a clinical practice level, allowing a more
customised approach to therapy with administration of an anti-the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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immunostimulating therapy, for example, administration of a cytokine,
including IL-7, IL-15, and granulocyte macrophage colony-stimulating
factor (GM-CSF), or co-inhibitory molecule blockade, such as anti-
programmed cell death receptor-1 (anti-PD-1) and anti-B and T lym-
phocyte attenuator (Chang et al., 2014; Sherwood and Hotchkiss,
2013), in immunosuppressed phases. Analysis of the individual genetic
signature of endotoxin tolerance may thus provide important and clin-
ically relevant information.
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